Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients
Rebecca Evans, Haruhide Kimura, Robert Alexander, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 35
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS
Brendan P. Lucey, Haiyan Liu, Cristina D. Toedebusch, et al.
Annals of Neurology (2023) Vol. 94, Iss. 1, pp. 27-40
Open Access | Times Cited: 44
The immunopathogenesis of narcolepsy type 1
Roland Liblau, Daniela Latorre, Birgitte Rahbek Kornum, et al.
Nature reviews. Immunology (2023) Vol. 24, Iss. 1, pp. 33-48
Closed Access | Times Cited: 43
Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1
Yves Dauvilliers, Emmanuel Mignot, Rafael del Río Villegas, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 4, pp. 309-321
Closed Access | Times Cited: 40
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Orexin pathway in Parkinson’s disease: a review
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Molecular Biology Reports (2023) Vol. 50, Iss. 7, pp. 6107-6120
Closed Access | Times Cited: 23
Effects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys
Motohisa Suzuki, Eri Shiraishi, James J. Cronican, et al.
British Journal of Anaesthesia (2024) Vol. 132, Iss. 3, pp. 541-552
Open Access | Times Cited: 8
Narcolepsies, update in 2023
Lucie Barateau, Fabio Pizza, Sofiène Chenini, et al.
Revue Neurologique (2023) Vol. 179, Iss. 7, pp. 727-740
Open Access | Times Cited: 20
Orexin 2 receptor‐selective agonist danavorexton ( TAK ‐925) promotes wakefulness in non‐human primates and healthy individuals
Rebecca Evans, Haruhide Kimura, Masato Nakashima, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 5
Open Access | Times Cited: 19
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
From past to future: 50 years of pharmacological interventions to treat narcolepsy
Éric Konofal
Pharmacology Biochemistry and Behavior (2024) Vol. 241, pp. 173804-173804
Open Access | Times Cited: 6
TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy
Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, et al.
Journal of Pharmacology and Experimental Therapeutics (2023) Vol. 385, Iss. 3, pp. 193-204
Open Access | Times Cited: 15
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
J Kron, Ryan J. Keenan, Daniël Hoyer, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 359-386
Open Access | Times Cited: 15
The present and future of synthetic orexin receptor agonists
Tsuyoshi Saitoh, Takeshi Sakurai
Peptides (2023) Vol. 167, pp. 171051-171051
Open Access | Times Cited: 13
Orexin receptor 2 agonist activates diaphragm and genioglossus muscle through stimulating inspiratory neurons in the pre-Bötzinger complex, and phrenic and hypoglossal motoneurons in rodents
Ryuji Yamada, Tatsuki Koike, Masanori Nakakariya, et al.
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0306099-e0306099
Open Access | Times Cited: 4
Narcolepsy and rapid eye movement sleep
Francesco Biscarini, Lucie Barateau, Fabio Pizza, et al.
Journal of Sleep Research (2024)
Open Access | Times Cited: 4
Alluring Potential to Accelerate Emergence and Ameliorate Opioid-induced Respiratory Depression without Antagonizing Analgesia: Danavorexton Enters the Anesthetic Landscape
Toshihiro Imamura, Max B. Kelz
Anesthesiology (2025) Vol. 142, Iss. 4, pp. 589-592
Closed Access
Isolated cataplexy without subjective and objective sleepiness in a hypocretin-deficient patient—is it narcolepsy?
Knar Gevorgyan, Janina Tepperberg, Tamara Scharf, et al.
SLEEP (2025)
Closed Access
Safety and pharmacodynamics of a single infusion of danavorexton in adults with obstructive sleep apnea experiencing excessive daytime sleepiness despite adequate use of CPAP
Richard Bogan, James Maynard, Rachel Neuwirth, et al.
Sleep Medicine (2023) Vol. 107, pp. 229-235
Open Access | Times Cited: 12
Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia
Emmanuel Mignot, Richard Bogan, Hélène A. Emsellem, et al.
SLEEP (2023) Vol. 46, Iss. 9
Open Access | Times Cited: 11
Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model
Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 220, pp. 173464-173464
Open Access | Times Cited: 17
The role of orexin neuron activity in sleep/wakefulness regulation
Chijung Hung, Akihiro Yamanaka
Peptides (2023) Vol. 165, pp. 171007-171007
Open Access | Times Cited: 9
Novel orexin receptor agonists based on arene- or pyridine-fused 1,3-dihydro-2H-imidazole-2-imines
Wentian Wang, Alok Ranjan, Wei Zhang, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 99, pp. 129624-129624
Open Access | Times Cited: 3
Orexin-mediated Motivated Arousal and Reward Seeking.
Theresa E. Bjorness, Robert Greene
Peptides (2024) Vol. 180, pp. 171280-171280
Closed Access | Times Cited: 3
Activated Wake Systems in Narcolepsy Type 1
Ling Shan, Suzan Linssen, Zoe Harteman, et al.
Annals of Neurology (2023) Vol. 94, Iss. 4, pp. 762-771
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top